Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
KYTX 
Kyverna Therapeutics, Inc. Common Stock (KYTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: KYTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $17.2
1 Year Target Price $17.2
| 3 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -17.59% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 160.01M USD | Price to earnings Ratio - | 1Y Target Price 17.2 |
Price to earnings Ratio - | 1Y Target Price 17.2 | ||
Volume (30-day avg) 6 | Beta - | 52 Weeks Range 1.78 - 8.28 | Updated Date 08/29/2025 |
52 Weeks Range 1.78 - 8.28 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.68 |
Earnings Date
Report Date 2025-08-12 | When - | Estimate -1.02 | Actual -0.97 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -31.08% | Return on Equity (TTM) -49.72% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -45750033 | Price to Sales(TTM) - |
Enterprise Value -45750033 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue 3341.48 | Enterprise Value to EBITDA - | Shares Outstanding 43245700 | Shares Floating 22471746 |
Shares Outstanding 43245700 | Shares Floating 22471746 | ||
Percent Insiders 12.03 | Percent Institutions 62.34 |
Upturn AI SWOT
Kyverna Therapeutics, Inc. Common Stock
Company Overview
History and Background
Kyverna Therapeutics is a clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases. It was founded to revolutionize the treatment of autoimmune diseases with next-generation cell therapies.
Core Business Areas
- Cell Therapy Development: Kyverna is dedicated to researching and developing innovative cell therapies, particularly focused on autoimmune diseases.
- Clinical Trials: The company conducts clinical trials to evaluate the safety and efficacy of its cell therapy candidates in treating various autoimmune conditions.
Leadership and Structure
Peter K. Heifetz is the Chief Executive Officer. The company has a management team with expertise in cell therapy, immunology, and clinical development. Their organizational structure is typical of a clinical-stage biotech company, centered around research, development, and clinical operations.
Top Products and Market Share
Key Offerings
- KYV-101: KYV-101 is an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy being developed for B cell-driven autoimmune diseases, including lupus nephritis, systemic sclerosis, and multiple sclerosis. Since it is in clinical trials, there is no current market share data available. Competitors for potential approval include companies developing treatments for the aforementioned autoimmune diseases, such as Roche, Bristol Myers Squibb, and others.
Market Dynamics
Industry Overview
The autoimmune disease therapeutics market is large and growing, driven by the increasing prevalence of autoimmune disorders and the development of novel therapies. Cell therapies represent a promising new approach, offering the potential for durable remissions.
Positioning
Kyverna is positioned as an innovator in the cell therapy space, focusing specifically on autoimmune diseases. Its competitive advantage lies in its novel CAR T-cell construct, KYV-101, and its potential to address unmet needs in autoimmune disease treatment.
Total Addressable Market (TAM)
The TAM for autoimmune disease therapies is estimated to be in the tens of billions of dollars. Kyverna is positioned to capture a portion of this market with its cell therapy platform, focusing initially on lupus nephritis, multiple sclerosis and systemic sclerosis.
Upturn SWOT Analysis
Strengths
- Novel CAR T-cell therapy platform (KYV-101)
- Focus on autoimmune diseases
- Experienced management team
- Strong pre-clinical and clinical data
Weaknesses
- Early stage clinical development
- High cost of cell therapy manufacturing
- Dependence on successful clinical trial outcomes
- Limited commercial infrastructure
Opportunities
- Expansion of KYV-101 to other autoimmune diseases
- Partnerships with larger pharmaceutical companies
- Advancements in cell therapy manufacturing technologies
- Positive clinical trial results driving market adoption
Threats
- Competition from existing and emerging therapies
- Regulatory hurdles and approval timelines
- Adverse events in clinical trials
- Pricing and reimbursement challenges
Competitors and Market Share
Key Competitors
- BMY
- RHHBY
- ABBV
Competitive Landscape
Kyverna Therapeutics competes with established pharmaceutical companies in the autoimmune disease space. Its competitive advantage lies in its CAR T-cell therapy approach, which has the potential to offer durable remissions compared to traditional treatments. However, it faces the challenge of demonstrating safety and efficacy in clinical trials and competing with established therapies.
Growth Trajectory and Initiatives
Historical Growth: Kyverna Therapeutics' growth is based on progressing its clinical trial pipeline and securing funding. It has shown growth by advancing KYV-101 through the clinical development process.
Future Projections: Future growth is dependent on successful clinical trial outcomes, regulatory approvals, and commercialization efforts. Analyst estimates vary based on these factors.
Recent Initiatives: Recent initiatives include advancing KYV-101 into Phase 2 trials for lupus nephritis and initiating trials for systemic sclerosis and multiple sclerosis.
Summary
Kyverna Therapeutics is a promising clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases. Its CAR T-cell therapy platform holds potential for durable remissions, but it faces challenges related to clinical development, regulatory approval, and competition. The company is well-positioned in the growing autoimmune disease therapeutics market, but its success hinges on positive clinical trial outcomes and securing adequate funding for its research and development programs.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be made based on individual risk tolerance and due diligence. Market share estimates are approximate and may vary based on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kyverna Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters Emeryville, CA, United States | ||
IPO Launch date 2024-02-08 | CEO & Director Mr. Warner Biddle | ||
Sector Healthcare | Industry Biotechnology | Full time employees 129 | Website https://kyvernatx.com |
Full time employees 129 | Website https://kyvernatx.com | ||
Kyverna Therapeutics, Inc., clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. The company's lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome and myasthenia gravis that is in phase 2 clinical trial; and for lupus nephritis. It is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing, as well as KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.